

FILE COPY



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C12N 15/62, 15/31, C07K 15/00 A61K 39/116	A1	(11) International Publication Number: WO 90/06366 (43) International Publication Date: 14 June 1990 (14.06.90)
(21) International Application Number: PCT/GB89/01462 (22) International Filing Date: 6 December 1989 (06.12.89) (30) Priority data: 8828523.4 7 December 1988 (07.12.88) GB 8913991.9 17 June 1989 (17.06.89) GB (71) Applicant (for all designated States except US): UNIVERSITY OF LEICESTER [GB/GB]; University Road, Leicester LE1 7RH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : HIRST, Timothy, Raymond [GB/GB]; AITKEN, Robert [GB/GB]; Adrian Building, University Road, Leicester LE1 7RH (GB). (74) Agents: WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5EU (GB).		(81) Designated States: AU, DK, FI, HU, JP, NO, US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HEAT-LABILE TOXIN B SUBUNIT FUSION PROTEINS (57) Abstract <p>A fusion protein comprises subunit B of <i>E. coli</i> heat-labile toxin (LTB) having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB. Such a fusion protein is obtained by culturing a host, such as a strain of <i>E. coli</i>, which has been transformed by a vector capable of expressing the fusion protein in that host. The fusion protein can be used as a vaccine.</p> <div data-bbox="191 1491 743 1869" style="border: 1px solid black; border-radius: 50%; padding: 20px; margin-top: 20px; text-align: center;">heat gene for LTB</div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

HEAT-LABILE TOXIN B SUBUNIT FUSION PROTEINS

The present invention relates to heat-labile toxin B subunit fusion proteins, to their preparation and to their use.

Toxigenic strains of Escherichia coli (ETEC) are among the most important causes of infant morbidity and mortality in the developing world. Any vaccine able to reduce the estimated 650 million cases (including about 800,000 deaths) per annum will clearly make a significant contribution to global health care. The development of such vaccines has to address the requirement to immunise against ETEC of different serotypes that produce a variety of adhesive antigens and one or both of two highly potent enterotoxins. It will also be necessary to evaluate the route and ease of vaccine administration, as well as vaccine storage, stability, and cost.

We have successfully generated a series of fusion proteins in which different portions of the gene for heat-stable enterotoxin (ST) are fused to the 3'-end of the gene encoding heat-labile enterotoxin B subunit (LTB). These LTB-ST recombinant hybrids possess all of the relevant properties for making them effective mucosal immunogens. We have also expressed another hybrid protein in which an epitope is fused to the carboxy-terminal of LTB. Fusion proteins in which an antigen or epitope is fused to the carboxy-end of LTB therefore represent a new way of effectively presenting the antigen or epitope to the immune system.

Accordingly, the present invention provides a fusion protein which comprises subunit B of E. coli heat-labile toxin (LTB) having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB.

The fusion proteins fold correctly and assemble into stable pentamer complexes. Natural LTB assembles to

- 2 -

holotoxin oligomers with adenylate-cyclase-activating subunit A in a molar ratio B:A of 5:1. The fusion proteins have a high affinity for binding to GM1-ganglioside, strong immunoreactivity toward neutralising anti-LT antibody and
5 neutralising antibody to the antigen or epitope fused to the LTB and the capacity to induce antibody responses to LTB and the fused antigen or epitope.

The fusion proteins employ LTB as a carrier for an antigen or epitope. Sufficient structural information must
10 be retained in the LTB gene to favour the formation of a chimaeric protein that binds to GM1-ganglioside and displays all LTB epitopes. Typically, therefore, the amino acid sequence of LTB up to amino acid 102 (Glu) is retained. The LTB may be human LTB (hLTB) or porcine LTB (pLTB), for
15 example..

A linker sequence can be provided between the carboxy-terminus of LTB and the antigen or epitope fused to the LTB. The sequence may have up to 10 amino acid residues, for example 2 or 3 residues. A suitable linker
20 sequence therefore is -Lys-Leu- or -Lys-Leu-Gly-.

The sequence at the joint between the LTB and the fused antigen or epitope preferably comprises -Lys-Leu-Gly-Pro-Gln-. The presence of this joint sequence is particularly beneficial in ensuring that the LTB portion
25 of the fusion protein and the fused antigen or epitope both fold correctly and consequently are properly presented to the immune system of a human or animal to which they may be administered. Further, the joint sequence is also particularly beneficial in enabling the fusion protein to
30 self-assemble into stable pentamers.

The joint sequence is provided where the fused antigen or epitope is joined to LTB. The joint sequence may comprise one or more of the carboxy-terminal amino acid residues of LTB and/or one or more of the amino-terminal
35 amino acid residues of the fused antigen or epitope.

Typically, the joint sequence follows immediately after the

- 3 -

LTB amino acid sequence. The final two or three amino-terminal residues of the fused antigen or epitope may form part of the joint sequence.

Any amino acid sequence having biological activity may be fused to the carboxy-terminus of the LTB. Any antigen or epitope from a pathogen responsible for a human or veterinary disease may be presented by the fusion protein. The antigen or epitope may be one which is capable of effecting an immune response, e.g. raising neutralising or non-neutralising antibodies or cellular immunity. A predicted antigenic determinant may be employed. The epitope may be up to 60, for example up to 20 amino acid residues in length.

A foreign amino acid sequence is therefore fused to LTB. This may therefore comprise an antigenic determinant capable of raising neutralising antibody to a pathogenic organism. The epitope may be derived from a virus, bacterium, fungus, yeast or parasite. More especially, the epitope may be derived from a type of human immunodeficiency virus (HIV) such as HIV-1 or HIV-2, hepatitis A or B virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus, influenza virus, coxsackie virus, the cell surface antigen CD4, Chlamydia trachomatis, RSV, HPV e.g. HPV 16, and the heat-stable enterotoxin of E. coli (ST).

LTB may therefore be fused to an immunogenic portion of ST. The LTB can be fused to the core and toxin regions of ST or to the toxin region only. For example, LTB can be linked to a portion of ST beginning at ST amino acid number 19(Pro) or at ST amino acid number 49 (Gly). Both the long and short hybrid proteins which result include the entire nineteen carboxy-terminal amino acid residues of ST which contain the six Cys residues necessary for native ST configuration.

The fusion proteins are prepared by recombinant DNA methodology. More particularly, a fusion protein is prepared by a process which comprises culturing a host,

- 4 -

which has been transformed with a vector capable of expressing the fusion protein in that host, under such conditions that the fusion protein is expressed. The fusion protein can then be isolated, typically in biologically pure form.

The preparation of the fusion protein therefore depends upon the provision of a DNA sequence encoding the fusion protein. The DNA sequence may be provided at its 5'-end with a sequence encoding a leader for the fusion protein so that the fusion protein is exported from the cytoplasm of the host cell in which it is expressed. Any appropriate leader sequence may be employed. Typically, however, DNA encoding the natural LTB leader sequence is provided immediately upstream of the DNA encoding the mature LTB sequence.

Thus a DNA sequence encoding the desired fusion protein is provided. An expression vector is prepared which incorporates the DNA sequence and which is capable of expressing the fusion protein when provided in a suitable host. Appropriate transcriptional and translational control elements are provided for the DNA sequence, in particular a promoter for the DNA sequence and a transcriptional termination site. The DNA sequence is located between translation start and stop signals in the vector. The DNA sequence is provided in the correct frame such as to enable expression of the fusion protein to occur in a host compatible with the vector.

The expression vector is used to transform a host. Cells harbouring the expression vector are grown so as to enable expression of the fusion protein to occur. The fusion protein may self-assemble into oligomers. Any appropriate host-vector system may be employed. The host may be a procaryotic or eucaryotic host. The vector may be plasmid. In that event, a bacterial or yeast host may be used for example a Gram negative bacillus such as E. coli or a Vibrio species, or S. cerevisiae. Alternatively, the

- 5 -

vector may be a viral vector. This may be used to transfect cells of a mammalian cell line, such as Chinese Hamster Ovary (CHO) cells, in order to cause expression.

A fusion protein expression vector may be prepared

5 by:

- (a) providing a LTB expression vector; and
- (b) ligating a gene encoding a desired antigen or epitope to the 3'-end of the LTB gene.

A vector capable of expressing LTB can be obtained by
10 cloning the LTB gene (Dallas, Infect. Immun. 40, 647-652, 1983) into a vector under the control of appropriate transcriptional and translational regulatory elements. If the fusion protein has a linker sequence between the LTB and the antigen or epitope, oligonucleotides corresponding to
15 the linker sequence can be synthesised and fitted to the 3'-end of the LTB gene or to the 5'-end of the gene encoding the antigen or epitope.

A preferred vector for use in obtaining a fusion protein expression vector is a vector which encodes LTB
20 having a carboxy-terminal extension. The coding sequence for the extension is selected such that it has a restriction site. A gene encoding an antigen or epitope it is desired to fuse to LTB can be inserted at this site. The coding sequence up to the restriction site is also selected such
25 that it encodes the correct amino acid residues for all or part of a desired linker sequence.

The invention therefore provides an expression vector which encodes LTB having a carboxy-terminal extension wherein the coding sequence for the extension has a
30 restriction site therein.

The invention further provides a process for the preparation of a fusion protein comprising LTB and an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB,
35 which process comprises (i) inserting a DNA sequence encoding the antigen or epitope into such a vector at the

- 6 -

said restriction site; and (ii) culturing a host harbouring the resultant vector under such conditions that the fusion protein is expressed.

The restriction site can be provided in any reading frame. More than one site can be present. The carboxy-terminal extension can be of any length, for example 5 to 10 and especially 8 amino acid residues. Preferred extensions, their coding sequences and the location of a restriction site for NaeI (____) are:

10 Lys Leu Gly Pro Gln Ala Gly Asp ***
AAG CTG GGT CCG CAG GCC GGC GAC TAG

Lys Leu Gly Pro Gln Gly Arg His ***
AAG CTG GGT CCG CAG GGC CGG CAC TAG

Lys Leu Gly Pro Gln Pro Ala Asp ***
15 AAG CTG GGT CCG CAG CCG GCT GAC TAG

*** denotes a stop codon. Such expression vectors can be prepared by synthesising oligonucleotides corresponding to the desired extension and fitting these to the 3'-end of the LTB gene. The resulting extended LTB gene
20 is provided in an expression vector with appropriate transcriptional and translational control elements.

The fusion protein that is expressed can be isolated. Where a fusion protein is expressed with a leader sequence, the protein will have been exported from the cytoplasm of
25 the cell in which it is expressed. A fusion protein expressed with a natural LTB leader sequence, for example, can therefore be isolated and purified from the periplasm of E. coli.

The purified fusion protein, killed toxigenic strains
30 of E. coli in which the fusion protein has been expressed and attenuated live vaccines capable of expressing the fusion protein can each be used as vaccines. The invention

- 7 -

consequently further provides a vaccine in which an active principle is selected from:

- (i) a fusion protein which comprises LTB having an antigen or epitope from a pathogen responsible for a human or animal disease fused to the carboxy-terminus of LTB;
- (ii) a toxigenic strain of E. coli in which the said fusion protein has been expressed and which has been killed; and
- (iii) an attenuated live vaccine capable of expressing the said fusion protein.

The vaccines typically also comprise a physiologically acceptable carrier or diluent. Conventional formulations, carriers and diluents may be employed. A suitable attenuated live vaccine may be an attenuated microorganism having a non-reverting mutation in each of two discrete genes in its aromatic biosynthetic pathway. Such microorganisms are described in EP-A-0322237. The microorganism is typically a pathogenic bacterium, for example from the genus Salmonella such as S. typhi, S. typhimurium, S. dublin or S. choleraesuis.



The non-reverting mutations may occur in any of the aroA, aroC, aroD and aroE genes. Preferably one of the non-reverting mutations is in the aroA gene. A suitable attenuated microorganism may harbour an expression cassette encoding a fusion protein such that the fusion protein can be expressed by the microorganism. For reliable expression through generations of the microorganism, an expression cassette should be stably inherited in the absence of antibiotic selection.



A vaccine may be administered by any convenient route. The choice of whether an oral route or a parenteral route, such as subcutaneous, intravenous or intramuscular administration, is adopted, of the dose and of the frequency of vaccination depends upon the purpose of the vaccination, whether a human or animal is being treated and the condition of the human or animal to which the vaccine is to be given.




- 8 -

Typically, however, the fusion protein is administered in an amount of from 1-1000 μ g per dose, more preferably from 10-100 μ g per dose, by either the oral or the parenteral route. For attenuated S. typhi, on the other hand, a dosage of 10^9 to 10^{11} S. typhi organisms per dose is generally convenient for a 70kg adult human patient, typically via the oral route.

The following Examples illustrate the invention. In the accompanying drawings:

10 Figure 1 shows the structure of pTRH5, pTRH6, pTRH13 and pTRH14 in which — denotes the LTB gene,  denotes the central core region of the STa2 gene and  denotes the carboxy-terminal region of the STa2 gene;

15 Figure 2 shows the immunoreactivity of the hybrid proteins expressed by E. coli K-12 strain G6 harbouring pTRH5 or pTRH6, in which the y-axis denote log toxin titre,  denotes monoclonal antibody against STa2 and  denotes monoclonal antibody against LTB; and

20 Figure 3 shows the results of an analysis for binding of anti-(hybrid protein) antibodies to ST determinants, in which the y-axis denotes absorbance at 450 nm;  denotes coating: hybrid antigen, probing antibody: pre-immunisation rabbit serum;  denotes coating: LTB, probing antibody: serum from immunised rabbit, and  denotes coating: hybrid antigen, probing antibody: immunised rabbit serum.

EXAMPLE 1

25 The construction of recombinant LTB-ST hybrid proteins was achieved by fusing the gene encoding the B subunit of heat-labile enterotoxin (LT) to two different portions of the gene encoding heat-stable enterotoxin (ST). This entailed the introduction of linker sequences into the ST gene and the use of a modified LTB gene, both of which have been described previously (Sanchez et al, Gene 64, 265-275, 1988; Sanchez et al, FEBS Letters, 208, 194-198,

- 9 -

1986; Sandkvist et al, J. Bacteriol, 169, 4570-4576, 1987). The STa2 gene was isolated as an AvaII/BamHI or DdeI/BamHI fragment from pSLM4 (Moseley et al, Infect. Immun. 39, 1167-1174, 1983). The Ava II- or Dde I-cut ends were fitted
 5 with oligonucleotides A or B (Sanchez et al, 1986; Sanchez et al, 1988), thus producing an end complementary for EcoRI-cut DNA,

A: AATTCGCCCCG pJS6: AvaII-EcoRI
 GCGGGCCCAG

10

SmaI

B: AATTCGCCCCGGGTCC pJS7: DdeI-EcoRI
 GCGGGCCCAGGAGT

SmaI

and introducing a SmaI site within each extension. The
 15 fragments were then ligated into the vector pUC18 that had been cut with EcoRI and Bam HI, thus producing pJS6 and pJS7.

Construction of pMM138 involved the isolation of the LTB gene from pWD615 (Dallas, Infect. Immun. 40, 647-652,
 20 1983) as an EcoRI/HindIII fragment and its subsequent ligation into pMMB66EH (Furste et al, Gene 48, 119-131, 1986) to produce pMMB68. The SpeI site incorporating the stop codon of the hLTB gene was mutated to a HindIII site as described by Sandkvist et al, to yield plasmid pMMB138.

25 Plasmids pJS6 and pJS7 were digested with EcoRI and SmaI. Plasmid pMMB138 was cut with HindIII, the large DNA fragment isolated and the projecting ends filled by T4 DNA polymerase (0.1 U/ μ l) and 100 nM dATP, dCTP, dGTP and dTTP. After precipitating the DNA fragment, it was further cut
 30 with EcoRI and the smaller fragment, coding for hLTB was isolated. This was mixed with the EcoRI/SmaI digested pJS6 and pJS7 at a fragment:vector ratio of 10:1 (w/w), heated to

- 10 -

70°C for 2 minutes and then allowed to incubate at room temperature. After addition of ATP (1mM), BSA (29 µg/ml), DTT (4mM), and T4 DNA ligase (1.4 u/µl) the mixture was incubated at 4°C overnight to ligate the DNA (final concentration of DNA was 63 ng/µl).

Competent *E. coli* K-12 strain G6 (Hardy *et al.*, Proc. Natl. Acad. Sci. 85, 7109-7113 1988) were transformed with the ligation mixtures. Transformants producing material that bound to GM1-coated microtitre wells and that was recognised by monoclonal antibodies against hLTB and STa2 were grown up, the plasmid DNA isolated, and the restriction pattern checked against that predicted. Plasmid pTRH5 was derived from a fusion of the gene coding for hLTB and pJS7; pTRH6 arose from a similar fusion with pJS6 (Figure 1). The predicted joint sequences of the resulting hybrid proteins were:

	+102	
pMMB138	GluLysLeuAlaProGlnLysArgTrpSTOP	
	+102	+19
20 pTRH5	GluLysLeuGly <u>ProGlnAspAla...</u>	
	+102	+49
pTRH6	GluLysLeu <u>GlyProGluSerMet...</u>	

The number 102 denotes the number of the hLTB amino acid. The ST amino acid residues are underlined and the number of the first is given. For the hybrid protein obtained from pTRH5, both the central core and the carboxy-terminal region of ST were present. Only the toxin region of ST was fused to hLTB in the recombinant protein expressed by plasmid pTRH6. *E. coli* CC118 harbouring pMMB138, pTRH5 or pTRH6 were deposited on 6 December 1989 at the National Collection of Industrial and Marine Bacteria, Aberdeen, GB under accession nos. NCIMB 40231,

- 11 -

NCIMB 40232 and NCIMB 40233 respectively.

The fusion proteins were obtained from periplasmic fractions of the E. coli K-12 strain G6 harbouring plasmid PTRH5 or PTRH6. Periplasmic fractions were isolated by lysozyme-ethylene diamine tetraacetic acid (EDTA) treatment and then analysed by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE). The migration position of the recombinant proteins corresponded to the molecular weights of chimaeric proteins containing the different lengths of STA2 fused to LTB.

EXAMPLE 2

The hybrid genes constructed in Example 1 which encode the hLTB-ST fusion protein were introduced into a controlled expression vector pMMB66EH (Furste et al, 1986). This put transcription under the control of the tac promoter and allowed synthesis to be regulated and the proteins hyper-produced by addition of isopropyl- β -D-thiogalactopyranoside (IPTG). The resulting plasmids were PTRH13 and PTRH14 which produced the fusion proteins also produced by TRH5 and PTRH6 respectively (Figure 1).

In more detail, PTRH5 was digested with restriction endonucleases EcoR1 and HindIII and a 0.65kb fragment was isolated. Similarly, PTRH6 was cleaved with EcoR1 and HindIII and a fragment of 0.56kb was obtained. pMMB66 was treated with EcoRI and HindIII, mixed with the isolated fragment from PTRH5 or PTRH6 and the DNA ligated with T4 DNA ligase to create PTRH13 (insert from PTRH5) and PTRH14 (insert from PTRH6). Transformants carrying the new plasmids were selected on the basis of their ability to produce, in response to the addition of 1mM IPTG, fusion proteins that would bind to GM1-coated microtitre plates and were recognised by monoclonal antibodies against LTB and ST.

Expression of the hybrid proteins in E. coli K-12

- 12 -

strain G6 carrying pTRH13 and pTRH14 resulted in synthesis of two polypeptides with molecular weights corresponding to the expected intact hybrid proteins. Periplasmic samples from E. coli pTRH13 and pTRH14 were precipitated with
5 ammonium sulphate (25-40% saturated), and dialysed against 1mM sodium phosphate pH7.2. The sedimentable aggregates generated during dialysis were collected by centrifugation and redissolved in 100mM sodium phosphate pH7.2, and then analysed by SDS-PAGE.

10 SDS-PAGE showed that the LTB-ST hybrid proteins retained an important property of LTB. They remained as discrete, stable pentamers when unheated prior to analysis by SDS-PAGE. However, they dissociated into monomers when
15 boiled. This indicated that the attachment of ST to LTB did not interfere with a critical structural feature of LTB that lends it stability and resistance to proteolysis.

EXAMPLE 3: Recognition of LTB-STa2 hybrids by anti-LT and anti-ST antibodies

The immunoreactivity of the LTB-STa2 hybrids was
20 evaluated in a GM1-based enzyme-linked immunosorbant assay (GM1-ELISA) using neutralising monoclonal antibodies against native LTB and ST to detect bound antigen. The assay is dependent on the ability of the hybrids to bind to GM1-ganglioside, and as such, a positive result provides
25 unequivocal evidence that the hybrids have retained the receptor-binding property characteristic of LTB. The results are shown in Figure 2. In Figure 2 it can be seen that both the long and short hybrids were strongly detected by neutralising anti-LT and anti-ST antibodies. We
30 therefore conclude that the hybrids exhibited several important structural features, including receptor GM1-binding and strong recognition by antitoxin antibodies, that are likely to play a vital role in their use as effective immunogens.

- 13 -

EXAMPLE 4: Toxicological properties

The purified LTB-ST hybrids were tested for ST toxicity in infant mouse assays. It was found that the shorter hybrid, encoded by pTRH14, was toxic. However, the longer and more stable construct, encoded by pTRH13 had very low toxicity indeed. No detectable toxicity was observed when 725 ng was injected intragastrically into infant mice, in which the sensitivity of the assay for native ST was 5 ng/mouse. This indicated that the longer LTB-ST hybrid was attenuated to at least 0.7% of the native toxicity.

EXAMPLE 5: Immunogenicity of LTB-STa2 hybrids

Immunisation of rabbits with partially purified preparations of the long and short hybrids gave high titre antibody responses to LTB and significant responses to ST. Rabbits were immunised with each hybrid protein employing a simple regimen of three injections, with Freund's Complete Adjuvant for priming and Freund's Incomplete Adjuvant for boosters. Sera from rabbits immunized with either of the two hybrids elicited strong anti-LTB antibody responses with titres over 40000. That the hybrids elicited antibody responses to the ST moiety was demonstrated by two experimental approaches.

(1) An inhibition ELISA was used in which microtitre plates were coated with a chemically conjugated cholera toxin (CT) B subunit/ST hybrid. Polyclonal antisera directed against CTB was shown to have no effect on the binding of a mouse monoclonal antibody against ST. In contrast however, the serum obtained from rabbits immunized with the recombinant hybrids exhibited a strong inhibitory effect on the binding of the mouse monoclonal antibody. This suggests the presence of competing anti-ST antibodies

- 14 -

in the rabbit immune system.

(2) A direct ELISA to discriminate between anti-LTB and anti-ST antibodies in the sera obtained from rabbits immunized with recombinant hybrids was developed.

5 Microtitre plates were first coated with either recombinant hybrids or purified LTB and then all B subunit epitopes blocked by the addition of a high titre anti-LTB polyclonal mouse serum (RJ11). This was followed by the addition of sera from the rabbits. The binding of rabbit IgG was
10 quantified with a horse radish peroxidase (HRO)-conjugated antibody. The results are shown in Figure 3.

In wells coated with LTB, the mouse serum efficiently blocked the subsequent binding of rabbit anti-LTB antibodies from the hybrid immune serum. In spite of this blocking
15 effect antibodies in sera from rabbits immunized with the LTB-STa2 bound strongly to wells coated with the recombinant hybrids. This strongly suggests that the sera from immunized rabbits contains antibodies directed against the ST determinant.

20 The biological significance of these results has been investigated further, using the infant mouse assay of Example 4 to test whether these anti-ST responses can neutralize native ST toxin. Initial observations suggest that sera from rabbits immunized with the longer LTB-ST
25 hybrid (pTRH13 gene product) are capable of neutralizing ST. The assay involved preincubation of native ST (40ng/ml) with serial dilutions of serum (e.g. 1/10, 1/60) followed by intragastric injection of infant mice. At both these dilutions the immune serum completely inhibited ST toxicity.

30 Previous findings by other researchers have suggested that ST-neutralizing antibodies are only elicited by ST-carrier conjugates which are ST-toxic. In view of our findings outlined above, we consider that our longer LTB-ST hybrid shows considerable promise as a LTB-ST toxoid antigen
35 which should elicit protective antibodies against

- 15 -

ST-producing ETEC.

EXAMPLE 6:

Plasmid pMMB138 (Sandkvist et al, 1987) encoding a mutant B subunit gene, etx B138, was used to insert a series of three oligonucleotide sequences which coded for the linker sequence, Lys Leu Gly Pro Gln, and convenient restriction sites for insertion of other oligonucleotides or DNA sequences specifying epitopes or antigens.

Plasmid pMMB138 was restricted with HindIII to give two DNA fragments whose recessed ends were filled in with the aid of T4 DNA polymerase. The larger of the two DNA fragments was then purified and ligated to three different annealed duplexes of synthetic oligonucleotides to generate three B subunit fusion vectors, designated pTRH100, pTRH101 and pTRH102. The sequences of oligonucleotides introduced were:

I	5' - GGGTCCGCAGGCCGGCGACTAGTGGATCCTCTAGA - 3'
	3' - CCCAGGCGTCCGGCCGCTGATCACCTAGGAGATCT - 5'
II	5' - GGGTCCGCAGGGCCGGCACTAGTGGATCCTCTAGA - 3'
20	3' - CCCAGGCGTCCGGCCGCTGATCACCTAGGAGATCT - 5'
III	5' - GGGTCCGCAGCCGGCTGACTAGTGGATCCTCTAGA - 3'
	3' - CCCAGGCGTCGGCCGACTGATCACCTAGGAGATCT - 5'

Oligonucleotide duplexes I, II and III were used to generate pTRH100, pTRH101 and pTRH102 respectively. The fusion joints at the 3'-end of the gene encoding the B subunit of Escherichia coli heat-labile enterotoxin, the amino acids encoded by the oligonucleotide inserts and restriction endonuclease sites are shown below. Each vector contains a single NaeI site in one of three codon reading frames for insertion of additional DNA fragments or synthetic oligonucleotides. All cloning steps were carried

out using standard procedures. Correct ligation and orientation of the fragments was analysed by fine restriction enzyme mapping.

+102
GluLysLeuGlyProGlnProAlaAsp***
pTRH102 GAAAAGCTGGGTCCGCAGCCGGCTGACTAGTGGATCCTCTAGAAGCTT
15 NaeI SpeI BamHI XbaI HindIII

Number +102 above the predicted amino acid sequence corresponds to the amino acid residue 102 in the mature B subunit (Leong et al, Infect. Immun. 48, 73-7, 1985).

20 A hybrid protein containing the B subunit fused to the (NANP)₃ repetitive epitope of the malaria parasite Plasmodium falciparum was produced by inserting an oligonucleotide sequence coding for the (NANP)₃ epitope into the NaeI site of plasmid pTRH102.

25 Plasmid pTRH102 was restricted with NaeI and BamHI and the larger fragment was purified. Two synthetic oligonucleotide sequences (shown below as A) encoding three

- 17 -

tandem repeats of amino acids NANP were annealed together and digested with BamHI. The digested oligonucleotide duplex and pTRH102-NaeI/BamHI fragment were ligated together and transformed into Escherichia coli K12 strain G6

5 (Enequist, et al., Eur. J. Biochem. 116, 227-33, 1981).

Recombinant plasmids were purified and their correct ligation and orientation were confirmed by fine restriction enzyme mapping. One of the correct plasmids was designated pTRH17.4. The nucleotide sequence and predicted amino acids
10 encoded at the 3' end of the gene are shown below (B).
Induction of the fusion product yielded a protein with the following properties:

- (i) recognition of receptor GM1-ganglioside
- (ii) assembly into defined oligomers
- 15 (iii) reaction by monoclonal antibodies against the LTB subunit and against the epitope (NANP)₃ using Western-blotting and GM1-bound enzyme linked immunosorbant assays.
- (iv) exported to the periplasm of Escherichia coli.

A. 5'-TAACGCTAACCCGAATGCGAACCCAAACGCAAACCCGTGAGGA
20 TCCGGGGGGAA-3'
3'-ATTGCGATTGGGCTTACGCTTGGGTTTGC GTTTGGGCACT
CCTAGGCCCCC-5'
BAMHI

+102
25 GluLysLeuGlyProGlnProAsnAlaAsnProAsnAlaAsnPro
AsnAlaAsnPro***

B. pTRH17.4 GAAAAGCTGGGTCCG CAGCCTAACGCTAACCCGAATGCGAACCCAAA
CGCAAACCCGTGAGGATCC

Number +102 corresponds to amino acid 102 in the
30 mature sequence of the B subunit of Escherichia coli
heat-labile enterotoxin. The underlined nucleotides in
pTRH17.4 are derived from the synthetic oligonucleotide in
A.

- 18 -

CLAIMS

1. A DNA sequence encoding a fusion protein which comprises subunit B of E. coli heat-labile toxin (LTB) having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus
5 of LTB.
2. A DNA sequence according to claim 1, wherein a linker sequence is provided between the carboxy-terminus of LTB and the said antigen or epitope.
3. A DNA sequence according to claim 1, wherein
10 the fusion joint comprises the amino acid sequence -Lys-Leu-Gly-Pro-Gln-.
4. A DNA sequence according to claim 1, wherein the LTB is fused to the core and toxin regions or to the toxin region of E. coli heat-stable toxin (ST).
- 15 5. A vector which comprises a DNA sequence as defined in claim 1 and which is capable, in a transformed host, of expressing the said fusion protein.
6. A vector according to claim 5, which is a plasmid.
- 20 7. A host transformed with a vector as claimed in claim 5.
8. A host according to claim 1, which is a transformed strain of E. coli.
9. A host according to claim 1, which is an
25 attenuated live vaccine.
10. A fusion protein which comprises LTB having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB.
11. A process for the preparation of a fusion
30 protein comprising LTB having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB, which process comprises culturing a transformed host as claimed in claim 7 under such conditions that the fusion protein is expressed.

- 19 -

12. A vaccine in which an active principle is selected from:

- (i) a fusion protein which comprises LTB having an antigen or epitope from a pathogen responsible for a human or animal disease fused to the carboxy-terminus of LTB;
- (ii) a toxigenic strain of E. coli in which the said fusion protein has been expressed and which has been killed; and

(iii) an attenuated live vaccine capable of expressing the said fusion protein.

13. An expression vector which encodes LTB, the LTB having a carboxy-terminal extension and the coding sequence for the extension having a restriction site therein.

14. A process for the preparation of a fusion protein comprising LTB having an antigen or epitope from a pathogen responsible for a human or veterinary disease fused to the carboxy-terminus of LTB, which process comprises

- (i) inserting a DNA sequence encoding the said antigen or epitope into a vector as claimed in claim 13 at the said restriction site; and

(ii) culturing a host harbouring the resultant vector under such conditions that the fusion protein is expressed.

1/1

Fig.1.




Fig.2.





Fig.3.



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 89/01462

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 12 N 15/62, C 12 N 15/31, C 07 K 15/00, A 61 K 39/116																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-bottom: 1px solid black;">Classification System</td> <td style="border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC⁵</td> <td style="padding: 5px;">C 12 N, A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	C 12 N, A 61 K											
Classification System	Classification Symbols																
IPC ⁵	C 12 N, A 61 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">WO, A, 86/06635 (BIOTECHNOLOGY AUSTRALIA PTY) 20 November 1986 see pages 33-38; claims</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2,5-14</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="text-align: center; vertical-align: top; padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">3,4</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Gene, volume 64, 1988, Elsevier Science Publishers B.V. (Biomedical Division), (Amsterdam, NL), J. Sanchez et al.: "Hybrid enterotoxin LTA::STa proteins and their protection from degradation by in vivo association with B-subunits of Escherichia coli heat-labile enterotoxin", pages 265-275 see the whole article cited in the application</td> <td style="text-align: center; vertical-align: top; padding: 5px;">3,4</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">FEBS Letters, volume 241, no. 1,2, December 1988, Elsevier Science Publishers B.V. (Biomedical Division), J. Sanchez et al.: "Genetic fusion of a non-toxic heat-stable enterotoxin-related decapptide antigen to ./.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-14</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO, A, 86/06635 (BIOTECHNOLOGY AUSTRALIA PTY) 20 November 1986 see pages 33-38; claims	1,2,5-14	Y	--	3,4	Y	Gene, volume 64, 1988, Elsevier Science Publishers B.V. (Biomedical Division), (Amsterdam, NL), J. Sanchez et al.: "Hybrid enterotoxin LTA::STa proteins and their protection from degradation by in vivo association with B-subunits of Escherichia coli heat-labile enterotoxin", pages 265-275 see the whole article cited in the application	3,4	A	FEBS Letters, volume 241, no. 1,2, December 1988, Elsevier Science Publishers B.V. (Biomedical Division), J. Sanchez et al.: "Genetic fusion of a non-toxic heat-stable enterotoxin-related decapptide antigen to ./.	1-14
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	WO, A, 86/06635 (BIOTECHNOLOGY AUSTRALIA PTY) 20 November 1986 see pages 33-38; claims	1,2,5-14															
Y	--	3,4															
Y	Gene, volume 64, 1988, Elsevier Science Publishers B.V. (Biomedical Division), (Amsterdam, NL), J. Sanchez et al.: "Hybrid enterotoxin LTA::STa proteins and their protection from degradation by in vivo association with B-subunits of Escherichia coli heat-labile enterotoxin", pages 265-275 see the whole article cited in the application	3,4															
A	FEBS Letters, volume 241, no. 1,2, December 1988, Elsevier Science Publishers B.V. (Biomedical Division), J. Sanchez et al.: "Genetic fusion of a non-toxic heat-stable enterotoxin-related decapptide antigen to ./.	1-14															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="padding: 5px;">26th March 1990</td> <td style="padding: 5px;">20 APR 1990</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px;">MIS D.S. ROWALCZYK</td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	26th March 1990	20 APR 1990	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	MIS D.S. ROWALCZYK							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
26th March 1990	20 APR 1990																
International Searching Authority	Signature of Authorized Officer																
EUROPEAN PATENT OFFICE	MIS D.S. ROWALCZYK																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	cholera toxin B-subunit", pages 110-114 see the whole article --	
A	Infection and Immunity, volume 50, no. 1, October 1985, American Society for Microbiology, F.A. Klipstein et al.: "Mucosal antitoxin response in volunteers to immunization with a synthetic peptide of Escherichia coli heat-stable enterotoxin", see pages 328-332 --	
P,X	WO, A, 89/02924 (PRAXIS BIOLOGICAL) 6 April 1989 see pages 21-22, 56-66; claims --	1,2,5-14
P,X	Infection and Immunity, volume 57, no. 4, April 1989, American Society for Microbiology, F. Schödel et al.: "Construction of a plasmid for expression of foreign epitopes as fusion proteins with subunit B of Escherichia coli heat-labile enterotoxin", see pages 1347-1350 -----	1,2,5-14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 8901462

SA 32995

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 20/04/90
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8606635	20-11-86	AU-A- 5861286	04-12-86
		EP-A- 0222835	27-05-87
		JP-T- 62503031	03-12-87
WO-A- 8902924	06-04-89	AU-A- 2813589	18-04-89